Next 10 |
2024-04-11 21:15:01 ET Jefferies analyst issues BUY recommendation for PMVP on April 11, 2024 07:46PM ET. PMVP was trading at $1.58 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations ...
2024-04-11 21:00:03 ET Kambiz Yazdi from Jefferies issued a price target of $5.00 for PMVP on 2024-04-11 19:46:00. The adjusted price target was set to $5.00. At the time of the announcement, PMVP was trading at $1.58. The overall price target consensus is at $31.33 with...
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients...
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) i n heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of th...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024 Ph...
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David Mack, Ph.D., President and Chief Executive Offic...
2024-01-18 16:57:20 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Ladenburg Thalmann starts PMV Pharmaceuticals at buy Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earning...
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from wor...
2024-01-05 16:10:58 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Ladenburg Thalmann starts PMV Pharmaceuticals at buy For further details see: PMV Pharmaceuticals names Michael Carulli as CFO
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
2024-04-11 21:15:01 ET Jefferies analyst issues BUY recommendation for PMVP on April 11, 2024 07:46PM ET. PMVP was trading at $1.58 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations ...
2024-04-11 21:00:03 ET Kambiz Yazdi from Jefferies issued a price target of $5.00 for PMVP on 2024-04-11 19:46:00. The adjusted price target was set to $5.00. At the time of the announcement, PMVP was trading at $1.58. The overall price target consensus is at $31.33 with...
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients...